IGF1 and neoplasm: The potential cancer risk associated with GH treatment has been an ongoing concern since its introduction due to the role of the GH-IGF-1 signaling pathways in fundamental cellular processes of mitosis, growth and cell survival, along with supporting experimental evidence of its impact on tumor formation (21, 22).